FDA Inspection 1302278 — Johanna Wilmink
The FDA completed an inspection of Johanna Wilmink on Dec 12, 2025 in Amsterdam. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Dec 12, 2025
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Amsterdam (Netherlands)
Additional Details
Clinical Investigator (CI)